908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith Sells 6,940 Shares

908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith sold 6,940 shares of the firm’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $7.08, for a total value of $49,135.20. Following the transaction, the chief financial officer now owns 102,930 shares of the company’s stock, valued at $728,744.40. This trade represents a 6.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

908 Devices Price Performance

MASS stock opened at $6.94 on Friday. The business has a fifty day moving average price of $5.03 and a 200 day moving average price of $3.53. 908 Devices Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $7.32. The stock has a market capitalization of $248.88 million, a price-to-earnings ratio of -3.92 and a beta of 0.29.

908 Devices (NASDAQ:MASS) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%. The firm had revenue of $11.78 million during the quarter, compared to analysts’ expectations of $11.90 million. On average, equities analysts expect that 908 Devices Inc. will post -1.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 908 Devices in a report on Saturday, May 24th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $5.33.

Institutional Investors Weigh In On 908 Devices

A number of hedge funds and other institutional investors have recently bought and sold shares of MASS. CWM LLC increased its stake in shares of 908 Devices by 541.2% in the 1st quarter. CWM LLC now owns 6,963 shares of the company’s stock valued at $31,000 after buying an additional 5,877 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of 908 Devices in the 1st quarter valued at $45,000. Two Sigma Advisers LP acquired a new stake in shares of 908 Devices in the 4th quarter valued at $30,000. Prudential Financial Inc. acquired a new stake in shares of 908 Devices in the 4th quarter valued at $34,000. Finally, Occudo Quantitative Strategies LP acquired a new stake in shares of 908 Devices in the 4th quarter valued at $36,000. 88.06% of the stock is owned by institutional investors and hedge funds.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.